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Received 7 March 2007; received in revised form 23 May 2007; accepted 31 May 2007AbstractObjective: Solitary fibrous tumours of the pleura (SFTP) are rare and can histologically be differentiated into benign and malignant forms. The
aim of this study is to present new cases, and discuss up-to-date preoperative examinations, the role of video-assisted thoracic surgery and long-
term outcome. Methods: Between 1993 and 2006, 27 SFTPs were diagnosed (14 females, mean age  SD, 62.3  9.6 years) at our institution.
Medical records were reviewed, and follow-up was obtained by repeated examinations or contact with general practitioners. Results: SFTPs were
associated with symptoms in 63% of all cases. In the six patients in which positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG)
was performed preoperatively, malignant lesions were all found to be positive. Complete resection was achieved by video-assisted thoracic
surgery in 15 and anterolateral thoracotomy in 12 patients. Mean hospital stay was shorter for patients operated by video-assisted thoracic
surgery compared to thoracotomy, 4.5 (range 3—6) versus 7.5 (range 4—25) days, respectively (p < 0.01). Histology revealed 17 benign and 10
malignant SFTP. Mean  SD tumour diameter of malignant SFTPs was larger than in benign forms, 11.9  7.1 versus 6.1  3.5 cm, respectively
(p < 0.01). Tumour recurrence was recognised in four patients with malignant SFTPs at a median time interval after surgery of 38 (range 6—122)
months, two late deaths occurred resulting from tumour recurrences. Conclusions: SFTPs can be treated minimally invasively by video-assisted
thoracic surgery with short hospital stay. Large SFTPs with increased FDG-uptake have a high likelihood for malignancy. Long-term follow-up is
mandatory in malignant SFTPs because of late recurrences associated with death.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Solitary fibrous tumours of the pleura (SFTP) are rare
neoplasms, and approximately 800 cases have been reported
in the literature so far [1]. It has been demonstrated by
immunohistochemical staining and electron microscopy that
these tumours are of mesenchymal origin [2,3]. A majority
are benign and characteristically grow as well-circum-
scribed, pedunculated lesions attached to the visceral and
less commonly to the parietal pleura [4]. Treatment of choice
is surgical excision and recurrence of these tumours is scarce
if resection is histologically complete [1,5]. However,
features of malignancy, characterised by poor circumscrip-
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doi:10.1016/j.ejcts.2007.05.027and nuclear pleomorphism, are found in 7—60% of SFTPs
[4,6,7]. Additionally, some benign SFTP may transform into
the malignant form even after several years [8]. Outcome of
malignant SFTPs is less favourable, and deaths related to
local invasion, recurrence, or metastases are reported in the
literature [4]. Therefore, there is a need to outline
parameters that characterise the underestimated malignant
variant and to better understand its biological behaviour.
A preoperative diagnosis of SFTP by radiological imaging
can be difficult and a reliable differentiation between
malignant and benign forms is often impossible with
computed tomography scanning (CT) or magnetic resonance
imaging (MRI). Benign and malignant SFTPs usually appear as
well circumscribed, homogeneous, and at times lobulated
masses with the density of soft tissue in CT scans. CT
heterogeneity, large tumour diameter, and pleural effusion
are more likely to be found in malignant forms, but may also
be observed in benign variants [1,4,9,10]. Furthermore,
diagnostic accuracy of CT-guided aspiration biopsy isSurgery. Published by Elsevier B.V. All rights reserved.
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Table 1
Clinical presentation
Finding Number of patients % of total
Asymptomatic 10 37
Symptomatic 17 63
Cough 7 25.9
Thoracic pain 7 25.9
Dyspnoea 3 11.1
Weight loss 2 7.4
Pneumonia 2 7.4
Clubbing 2 7.4
Hypoglycaemia 1 3.7unsatisfactory [6,8,11]. To date there is very little data
available from positron emission tomography (PET) with
[18fluorine]fluorodeoxyglucose (FDG) performed in patients
with these tumours [12,13]. FDG-PET could possibly predict
or rule out malignancy in SFTP preoperatively and reveal
metastatic recurrence, an event rarely observed in these
tumours [4].
Recently, video-assisted thoracoscopic surgery (VATS) has
been introduced for the treatment of SFTP which is thought
to result in shorter hospital stay and less postoperative
morbidity, but comparative data between VATS and thor-
acotomy are scant [5]. In order to define the clinical and
radiological pattern of benign and malignant SFTP more
accurately and evaluate the role of VATS as a less invasive
treatment option we summarise our experience in the
management of SFTP.2. Materials and methods
From January 1993 toMarch 2006, 27 SFTPswere diagnosed
in 27 patients (14 females, mean age  SD, 62.3  9.6 years)
at our institution. The medical records were reviewed, and
follow-up was obtained by repeated examinations of patients
or contact with the primary care physician. No history of
exposure to asbestos was recorded in any of the patients.
All patients underwent chest X-ray and computer
tomography (CT) of the chest preoperatively. Whole body
FDG-PET was performed in six patients. FDG uptake was
qualitatively assessed, positivity and likelihood of malig-
nancy was defined as focally increased FDG uptake in
comparison with the background not related to physiologic
processes, combined with a tumour diameter >10 cm or
inhomogeneous FDG uptake.
The diagnosis of SFTP was confirmed by typical histomor-
phologic findings of a solid spindle cell component, and a
diffuse sclerosing component combined with matching
immunohistochemical staining (positive for vimentin and/
or CD34, negative for keratin and/or S-100 protein). SFTPs
were classified as benign or malignant according to the
histologic criteria published previously [4]. Malignancy was
assumed if one ormore of the following criteria weremet: (1)
4 mitotic figures per 10 high-power fields (HPF), (2)
presence of necrosis or haemorrhage, (3) pleomorphism
based on nuclear size, nuclear crowding and overlapping, and
the presence of nuclear atypia.
Student’s t-tests for normally distributed, and Mann—
Whitney U-tests for not normally distributed data were
performed for comparisons between groups. For comparison
of frequencies x-square test of independence or a Fisher’s
exact test when any of the expected tumour features were
fewer than five was used. Statistical significance was
assumed at a probability of p < 0.05.3. Results
3.1. Clinical presentation
SFTPs were associated with symptoms in 17 patients
(63%), whereas 37% of our patients were asymptomatic.Cough and thoracic pain were the primary symptoms
occurring each in a quarter of all patients. Symptomatic
hypoglycaemia was found in only one patient (3.7%).
Twelve patients (44.4%, four females) were smokers or ex-
smokers (mean pack years  SD, 24.6  16.6 years). Further
data on clinical presentation are given in Table 1.
3.2. Preoperative studies
In all patients, standard chest X-ray and CT revealed a
pleural tumour. The origin of the tumour was determined in
the left hemithorax in 16 patients (59.3%), whereas the right
hemithorax was involved in 40.7%. SFTPs were slightly more
often found in the lower (55.6%) than in the upper lobe area
(40.7%). In one case (3.7%) the lobe of origin could not be
determined. Pleural effusion was found in one patient (3.7%)
only.
Tumours appeared inhomogeneous on CT in three patients
with malignant SFTP and in two patients with benign SFTP
( p = ns). Tumour necrosis in histology was only found in
patients with malignant lesions. Tumour invasion into the
chest wall was radiologically suspected in one patient with
malignant SFTP, which was subsequently confirmed during
surgery and by histology. Calcification of the tumour was
detected by CT in one patient with malignant and in two
patients with benign SFTP.
In six patients, three with malignant and three with
benign SFTPs, an integrate 18F-fluorodeoxyglucose PET-CT
was performed preoperatively. PET-CTwas positive in three
patients who had a histologically proven malignant SFTP,
whereas criteria for positivity were not met in patients with
benign SFTP. No signs of lymph node or distant metastases
were found in the three cases of malignant SFTPs.
Preoperative CT-guided transcutaneous aspiration biopsy
was performed in five patients (18.5%) leading to the correct
histologic diagnosis in two cases. A typical example of a CT
scan from a patient with SFTP is shown in Fig. 1.
In seven patients (25.9%) the tumour was present on
radiological imaging performed more than 6 months pre-
viously (median 42 months, range 7—156 months) and had
been judged as a benign lesion. Patients were finally referred
for surgery because of an increase in size or emerging clinical
symptoms. In three of these seven patients the SFTPs were
histologically found to be malignant.
Lung function testing revealed a moderate restrictive
ventilatory defect in one patient caused by a large SFTP
(23 cm  21 cm  7 cm). An obstructive pattern was deter-
mined in three other patients with COPD (GOLD-stage I—II)
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Fig. 1. Computed tomographic scan showing a left-sided broad based solitary
fibrous tumour of the pleura with a characteristic pedicle (histological exam-
ination revealed a benign variant).
Fig. 2. Intraoperative photograph showing the characteristic pedicle (Pe) of a
large solitary fibrous tumour of the pleura. L: lung; Ph: phrenicus nerve; P:
pericard; T: tumour; D: diaphragm; Pl: pleura.due to smoking. Bronchoscopy was performed in eight
patients and provided no relevant additional information.
3.3. Treatment
Complete resection was achieved in all 27 patients. In all
patients a single lesion was found at surgical exploration.
Tumours originated from the visceral pleura in 88.8%, a
pedicle was present in 59.3% of the cases (e.g. Fig. 2). In
three cases (11.1%) the lesions arose from the parietal pleura
(two of them were malignant). Macroscopically a tumour-
capsule was found in 74.1%.
In 85.2% of the cases removal of the neoplasm was either
accomplished by dividing the pedicle close to or with a small
rim of lung parenchyma (tumours arising from the visceral
pleura) or by a pleural excision (tumours originating from the
parietal pleura). Lobectomy was necessary in one and
pneumonectomy in three patients due to extensive adhesions
and intraparenchymal extension of the tumour.
Anterolateral thoracotomy was performed in 12 patients
(44.4%, in 1 patient anterolateral thoracotomy was combined
with upper median sternotomy because of very large tumour
size), whereas surgical resection was accomplished by VATS in
15 patients (55.6%). Mean hospital stay was significantly
shorter for patients operated by VATS than by thoracotomy,
4.5 (range 3—6) versus 7.5 (range 4—25) days, respectively
( p < 0.01). Duration of hospitalisation was longer in patients
with malignant SFTPs (median 8, range 3—25 days) compared
to patients with benign SFTPs (median 5, range 3—7 days,
p < 0.05).
Major perioperative complications occurred in one patient
in the VATS group (bleeding) and in three patients undergoing
thoracotomy (one patient with sepsis, one patient with
pneumopleural leakage, one patient with atrial fibrillation,
liver and renal failure). There was no perioperative mortality
reported in either group.As expected, mean tumour diameter was larger in the
thoracotomy group, 12.4 cm (range 3.0—23 cm) versus
4.9 cm (range 2.0—9.5 cm) in the VATS group ( p < 0.01).
3.4. Pathology
Maximal tumour diameter ranged from 2 cm in the
smallest to 23 cm in the largest tumour with an average of
8.2 cm. Mean tumour volume was 460 cm3 (range 1.6—
4301 cm3).
Histological examinations revealed 17 benign (63%) and 10
malignant (37%) SFTPs. All malignant tumours showed more
than 4 mitoses per 10 HPFs. Malignant SFTPs were bigger and
occurred more often in men than in women. Malignant SFTPs
were equally distributed between smokers and non-smokers.
Recurrence of the tumour was only recognised in malignant
forms.
Immunohistochemical analysis was performed in 23 cases.
All tumours were positive for CD34 and/or vimentin, while
none showed a positive reaction to antikeratin antibodies.
Comparative data between malignant and benign SFTPs
are given in Table 2. A typical example of histological
photomicrographs from a SFTP is shown in Fig. 3.
3.5. Follow-up
Median follow-up time for all patients was 54 (range 6—
157) months. Local recurrence of the tumour was recognised
in the CT scan of four patients (14.8%) at a median time
interval after surgery of 38.5 (range 6—122) months. All
relapses occurred in patients with malignant SFTPs, and all of
them were reoperated and the diagnosis of a relapse was
histologically confirmed. In total three deaths occurred: one
patient had a total of three local recurrences and eventually
died of distant metastases, one patient died of local
recurrence of the tumour, and one patient died of an illness
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Table 2
Comparison of malignant and benign SFTPs
Malignant (n = 10) Benign (n = 17) p
Age (years) 66.5  6.8 59.9  10.6 0.09
Women (%) 30 64.7 0.60
Men (%) 70 35.3 0.007
Smokers (%) 40 47.1 0.52
Symptomatic (%) 80 52.9 0.16
Tumour diameter (cm) 11.9  7.1 6.1  3.5 0.009
Tumour volume (cm3) 1218  1821 147  276 0.02
Tumour recurrence (%) 40 0 0.005
Values are expressed as means  standard deviation (where applicable).
Values in bold are statistically significant.unrelated to the SFTP. Cumulative survival after operation is
illustrated in Fig. 4.Fig. 4. Kaplan—Meier curve showing the cumulative survival probability in
patients with SFTPs following operation.4. Discussion
Solitary fibrous tumours of the pleura (SFTP) are rare
and their clinical characteristics are not well known. There
are only a few studies including an appropriate number
of malignant SFTPs and reporting adequate follow-up
[1,11,14,15]. Because some of these tumours are asympto-
matic and do not show conventional radiological signs ofFig. 3. Photomicrographs of a solitary fibrous tumour of the pleura. The low
powermagnification haematoxylin-eosin stain (A) shows a high cellular solitary
fibrous tumour with characteristic ropey collagen bundles. Higher power
magnification haematoxylin-eosin stain (B) demonstrating variable cytological
atypia and pleomorphism with occasional mitoses and apoptotic cells. Immu-
nohistochemical staining is strongly positive for CD34 (C). A variable prolif-
erative activity can be detected in a MIB-1/Ki-67 staining (D). Staining for CD31
(E) highlights the characteristic staghorn vascular pattern. Immunohistochem-
ical stainings for CD99 are variably positive in SFTPs (F). Original magnifica-
tions 10 (A), 80 (B, C, D, F) and 40 (E).malignancy, referral for surgery is sometimes delayed [11].
Furthermore, the diagnostic value of CT-guided aspiration
biopsy has been shown to be poor and may not be helpful in
making a decision about the need for surgery [6,7,11]. In our
series, surgery was delayed in seven (26%) patients (median
42, range 7—156 months) which is similar to previously
reported data [11]. In three of these seven patients the SFTPs
were histologically found to be malignant, which emphasises
the need for early diagnosis and treatment even in
asymptomatic cases. There are no specific symptoms that
allow differentiation between benign and malignant forms of
SFTPs. In contrast to an earlier report, we did not find
significantly more symptomatic patients in the malignant
group than in the benign group [11]. Interestingly, malignant
tumours occurred more often in men compared to women in
our study, whereas England et al. [4] found malignant
tumours evenly distributed between genders. The size and
volume of malignant tumours were greater than in benign
SFTPs. Although data from previous series are inconsistent,
most authors showed that a larger tumour size is associated
with a higher risk of malignancy and local recurrence
[1,4,11].
A preoperative diagnosis of SFTP based on radiological
imaging can be difficult and a differentiation between
malignant and benign forms is often impossible by CTor MRI.
In our series inhomogeneous appearance and calcification of
the tumour did not discriminate between malignant and
benign SFTP, and CT-guided biopsy of the tumour established
the correct diagnosis in only two cases out of five which is in
accordance with previously published studies [11]. Most
authors feel that diagnostic accuracy of CT-guidedaspiration
biopsy in SFTPs is unsatisfactory [6,8,11]. In our opinion CT-
guided biopsy may be helpful in cases where diagnosis of
SFTP is uncertain. In an attempt to improve diagnostic
accuracy, we retrospectively looked at FDG-PET-scans, and
found PET positivity in all patients with malignant SFTPs. To
our knowledge there are only a few case reports on FDG-PET
in SFTP in the literature. Robinson [12] reported no FDG
uptake in twobenign SFTPs, andCortes et al. [13] found FDG-
PET negativity in three benign lesions. Because the small
number of patients limits our findings and the available
information in the literature, prospective studies including a
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the accuracy of FDG-PET in differentiating malignant from
benign SFTPs and to define its role in clinical practice. We
believe all patients with SFTPs should undergo surgery
without delay, as SFTPs can progress in size causing
symptoms and may transform to a malignant tumour,
therefore the value of preoperative FDG-PET would be
limited to exclusion of tumour metastasis, an event rarely
observed in SFTPs [4]. However, some centres apply a
strategy of watchful waiting in asymptomatic SFTP and
operations may be delayed in countries with long waiting
lists. In this setting, an FDG-PET positive SFTP could be
consideredmalignant and should be operatedwithout delay.
Furthermore, FDG-PET might be suitable to detect metas-
tases after surgery in patients with malignant SFTP.
We observed a malignant histology in 37% of cases on the
basis of criteria suggested by England et al. [4]. The same
criteria have been used in recently published studies and they
are accepted by the American registry of pathology
[1,6,11,16]. The percentage of malignant tumours is similar
to that found in other series (e.g. 37% in the study of
Magdeleinat et al. [11], 36% in the study of England et al. [4]),
but there is a considerable variability ranging from 7 to 60%
reported in other studies [5—7]. A likely explanation for the
variability might be the difficulty in establishing the criteria
for malignancy in large tumours due to heterogeneity of the
lesion.
Recently VATS has been reported to be a promising surgical
approach for resection of SFTPs resulting in less invasive
surgery and therefore minimising postoperative morbidity
[5]. Other advantages of VATS are better cosmetic results and
in theory less costs because of shorter hospital stays. We
found a significantly shorter hospital stay (4.5 days) in
patients operated by VATS compared to patients operated by
anterolateral thoracotomy (7.5 days). There was a tendency
towards fewer postoperative complications occurring in the
VATS group (6.7%) in comparison with thoracotomy (25%).
Takahama et al. [5] reported a mean duration of hospital stay
of 8.6 days in their series of 13 patients including 9 patients
operated by VATS; further comparative data between
thoracotomy and VATS in SFTPs are lacking. Of note, very
large lesions (e.g. >10 cm diameter) and tumours with
radiological signs of invasion into the chest wall or
intrathoracic organs are not suitable for VATS, and tumour
diameter was significantly larger in the thoracotomy group in
our study. Furthermore, the extent of resection possibly
influences postoperative morbidity and the length of hospital
stay, although the differences between VATS and thoracot-
omy found in our series could not be entirely explained by the
different extent of resection.
Local recurrences of SFTPs after complete surgical
resection are not uncommon in malignant forms, but are
exceptionally rare in benign lesions [1,4]. If recurrence does
occur in benign lesions, this may be due to incomplete
resection, unrecognised malignancy or growth of an unre-
lated second SFTP, which has been described previously [4].
We observed recurrence of the tumour during follow-up in 4
out of 10 patients with malignant SFTPs, although some
authors report less recurrences [11,17], and in none with
benign SFTPs, which is in accordance with other series [4,7].
A possible explanation for these differences could bedifferent radiological methods used at follow-up. It must
be stressed that the minimal-invasive approach by VATS
should not compromise an oncologically sound operation, and
therefore the type of operation (VATS vs thoracotomy) should
not influence tumour recurrence.
De Perrot et al. [1] suggested a follow-up plan after
resection of malignant SFTPs with half-yearly radiologic
controls by CT in the first 2 years and yearly thereafter.
Especially in malignant lesions a long-term follow-up is
mandatory because of possible late recurrences, which can
be locally aggressive, and lead to death through local
invasion and compression, which occurred in two of our
patients. In case of recurrence, surgical resection is the
treatment of choice with a good chance for complete cure
[1]. There are only a few cases described in the literature
concerning adjuvant radiotherapy or chemotherapy in
malignant SFTPs and their role needs to be established
[11].
In conclusion, we found that large SFTPs with increased
FDG-uptake have a high likelihood for malignancy, but the
role of FDG-PET in clinical practice has to be further defined.
VATS is associated with a short hospital stay and minor
postoperative morbidity, and is therefore our preferred
surgical approach for resection of SFTPs smaller than 10 cm.
Long-term follow-up is mandatory in malignant SFTPs
because of late recurrences associated with death.
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